<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918667</url>
  </required_header>
  <id_info>
    <org_study_id>EP-1007</org_study_id>
    <nct_id>NCT04918667</nct_id>
  </id_info>
  <brief_title>Effect of Gamma-cyclodextrin on the Bioavailability of Berberine</brief_title>
  <official_title>A Phase I, Randomized, Crossover, Double-blind, Pharmacokinetic Study of Berberine Released From Cyclodextrin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuroPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scientific Center of Drug and Medical Technologies Expertise of the Ministry of Health, Armenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiomed LLC, Armenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Fine Organic Chemistry of the National Academy of Science, Armenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phytomed AB, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EuroPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will evaluate the relative bioavailability of Berberine (BB) from capsules&#xD;
      containing Indian Barberry (Berberis aristate DC.) Bark and Root Extract in the blood plasma&#xD;
      of healthy subjects after oral administration of:&#xD;
&#xD;
      A. Capsules containing Berberine and GCD (BBA Berberine MetX™ Ultra Absorption, 250 mg) B.&#xD;
      Capsules containing Berberine (BB, Berberine MetX™, 500 mg) - (reference product).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Background&#xD;
&#xD;
      A growing body of evidence suggests that gamma-cyclodextrin (GCD) can increase the clinical&#xD;
      efficacy of water-insoluble biologically active compounds with low bioavailability. GCD is&#xD;
      the most bio adaptable and helpful to increase the absorption of many drugs, including&#xD;
      Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract by forming&#xD;
      inclusion complexes or GCD/drug conjugates.&#xD;
&#xD;
      Berberine has been recommended in traditional practice and recognized by modern science to&#xD;
      support healthy blood sugar†, cholesterol and triglyceride levels, and overall metabolic&#xD;
      health. But despite these findings, standard Berberine can still be difficult for the body to&#xD;
      absorb and use effectively.&#xD;
&#xD;
      It's estimated that only about five percent of any given dosage of Berberine makes it into&#xD;
      the bloodstream, so finding a way to enhance absorption is key to the full advantage of its&#xD;
      benefits.&#xD;
&#xD;
      Hypothesis: gamma-cyclodextrin increases absorption and bioavailability of Berberine from&#xD;
      Berberine MetX™ Ultra Absorption capsules.&#xD;
&#xD;
      The study aims to provide experimental evidence supporting or rejecting this hypothesis.&#xD;
&#xD;
      This will be a double-blind, crossover design, pharmacokinetic study, where 16 healthy human&#xD;
      volunteers will be randomly assigned to receive two different formulations BBA, and BB, in&#xD;
      two consecutive phases of the study:&#xD;
&#xD;
        -  Phase A. All patients take capsules BBA., provide blood samples in 0.5, 0.75, 1, 2, 4,&#xD;
           6, 12, 24, and 48 hours (9 points) after administration following washout period for two&#xD;
           weeks.&#xD;
&#xD;
        -  Phase B. All patients take capsules BB, provide blood samples in 0.5, 0.75, 1, 2, 4, 6,&#xD;
           12, 24, and 48 hours (9 points) after administration following washout period for two&#xD;
           weeks.&#xD;
&#xD;
      Subjects will be in the clinic from not less than 11 hours pre-dose to ensure at least 10&#xD;
      hours fasting before administering the investigational product. They will remain in the&#xD;
      facility post-dose until at least 24 hours each period, provided they are not suffering from&#xD;
      any adverse event.&#xD;
&#xD;
      The concentration of Berberine in all blood samples will be determined using a validated for&#xD;
      a limit of detection, accuracy, and precision analytical method (HPLC-MS) with the internal&#xD;
      standard - digoxin. Appropriate mathematical methods and Kinetic 4.4.1 software will be used&#xD;
      to generate basic pharmacokinetic parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration versus time curve (AUC, expressed in ng x h/mL) of berberine incorporated in gamma-cyclodextrin</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72 and 96 hours, post-dose</time_frame>
    <description>The changes from the baseline the concentration (ng/ml) of berberine in blood plasma obtained after oral administration of the experimental product BBA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration versus time curve (AUC, expressed in ng x h/mL) of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72 and 96 hours, post-dose</time_frame>
    <description>The changes from the baseline the concentration (ng/ml) of berberine in blood plasma obtained after oral administration of the active comparator BB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The absorption rate constants (Ka, h-1) of berberine incorporated in gamma-cyclodextrin</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72 and 96 hours, post-dose</time_frame>
    <description>The absorption rate constants (Ka, h-1) of berberine obtained after oral administration of the experimental modified product BBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absorption rate constants (Ka, h-1) of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72 and 96 hours, post-dose</time_frame>
    <description>The absorption rate constants (Ka, h-1) of berberine obtained after oral administration of the active comparator BB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax, ng/ml) of Berberine incorporated in gamma-cyclodextrin</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax, ng/ml), of berberine obtained after oral administration of the experimental modified product BBA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax, ng/ml) of Berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax, ng/ml), of berberine - obtained after oral administration of the active comparator BB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration, Tmax (h) of berberine incorporated in gamma-cyclodextrin</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Time to reach maximum plasma concentration, Tmax (h) of berberine obtained after oral administration of the experimental modified product BBA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration, Tmax (h) of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Time to reach maximum plasma concentration, Tmax (h) of berberine obtained after oral administration of the active comparator BB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absorption time MAT (h) of berberine incorporated in gamma-cyclodextrin</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Mean absorption time MAT (h) of berberine obtained after oral administration of the experimental modified product BBA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absorption time MAT (h) of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Mean absorption time MAT (h) of berberine obtained after oral administration of the active comparator BB</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relative bioavailability (%) of berberine incorporated in gamma-cyclodextrin</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>Relative bioavailability (%) of Berberine from 0 to 96 hours defined as the ratio of AUC0-96h for the tested formulation (Berberine MetX™ Ultra Absorption capsules) to the AUC0-96h obtained for the reference product (100%, Berberine MetX™ Ultra capsules), given by the same route of administration in the same dose. F= AUCBBA/AUCBB x 100%</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of gamma-cyclodextrin on absorption rate constant (Ka, h-1) of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>The difference in the absorption rate constants (Ka, h-1) of berberine obtained after oral administration of BBA, and BB.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of gamma-cyclodextrin on the maximal concentration (ng/ml) of berberine in blood</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>The difference in Cmax (ng/ml) of berberine obtained after oral administration of BBA and BB.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of gamma-cyclodextrin on time (h) to reach maximum plasma concentration of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>The difference in Tmax (h) of berberine obtained after oral administration of BBA, and BB.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of gamma-cyclodextrin on Mean absorption time (h) of berberine</measure>
    <time_frame>0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours, post-dose</time_frame>
    <description>The difference in MAT (h) of berberine obtained after oral administration of BBA, and BB.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Drug Absorption</condition>
  <arm_group>
    <arm_group_label>Berberine MetX™ Ultra Absorption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 healthy subjects will receive orally 500 mg of berberine in two capsules of Berberine MetX™ Ultra Absorption.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine MetX™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 healthy subjects will receive orally 500 mg of berberine in one capsule of Berberine MetX™ (reference product).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Berberine incorporated in gamma cyclodextrin</intervention_name>
    <description>Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin</description>
    <arm_group_label>Berberine MetX™ Ultra Absorption</arm_group_label>
    <other_name>Berberine MetX™ Ultra Absorption, 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract</description>
    <arm_group_label>Berberine MetX™</arm_group_label>
    <other_name>Berberine MetX™, 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers, as determined by medical history, physical examination, and&#xD;
             clinical laboratory testing,&#xD;
&#xD;
          -  Willingness to stay in the unit overnight for the duration of the study,&#xD;
&#xD;
          -  Provide a signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  overweight (BMI &gt;35 kg/m2),&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  lactation,&#xD;
&#xD;
          -  drug abuse,&#xD;
&#xD;
          -  use of dietary supplements or any form of medication (with the exception of oral&#xD;
             contraceptives),&#xD;
&#xD;
          -  heavy smokers, or ex-smokers with a remote history (&gt; one pack/day),&#xD;
&#xD;
          -  frequent alcohol consumption (&gt;20 g ethanol/d),&#xD;
&#xD;
          -  adherence to a restrictive dietary regimen,&#xD;
&#xD;
          -  physical activity of more than 5 h/wk,&#xD;
&#xD;
          -  respiratory tract infections, or suspicion thereof in the last 14 days before dosing,&#xD;
&#xD;
          -  history or presence of disease in the kidneys and heart, lungs, liver,&#xD;
             gastrointestinal tract, endocrine organs or other conditions such as metabolic disease&#xD;
             known to interfere with the absorption, distribution, metabolism, and excretion of&#xD;
             drugs,&#xD;
&#xD;
          -  malignancy,&#xD;
&#xD;
          -  autoimmune disorders such as (but not limited to) lupus erythematosus, multiple&#xD;
             sclerosis, rheumatoid arthritis, or sarcoidosis,&#xD;
&#xD;
          -  any other disease or condition, which, in the opinion of the Investigator, would make&#xD;
             the subject unsuitable for this study,&#xD;
&#xD;
          -  currently taking medications known to be CYP2C9 inducers (i.e., carbamazepine and&#xD;
             rifampicin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aghavni Ginosyan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Center of Drug and Medical Technologies Expertise of the Ministry of Health, Armenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samvel Hairumyan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CARDIOMED Family Health Center, LLC of the Ministry of Health of the Republic of Armenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Areg Hovhannisyan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Fine Organic Chemistry of the National Academy of Science, Armenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander G Panossian, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Phytomed AB, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander G. Panossian, PhD</last_name>
    <phone>+46733306226</phone>
    <email>ap@phytomed.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Hansgate</last_name>
    <email>jhansgate@europharmausa.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CARDIOMED Family Health Center, LLC of the Ministry of Health of the Republic of Armenia</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Samvel Hairumyan, PhD, MD</last_name>
      <phone>+37493203057</phone>
      <email>hsamvel@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Fine Organic Chemistry of the National Academy of Science</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Areg Hovhannisyan, PhD Areg Hovhannisyan, PhD, PhD</last_name>
      <phone>+37494282018</phone>
      <email>areglab@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Drug and Medical Technologies Expertise</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Aghavni Ginosyan, PhD, MD</last_name>
      <phone>+37493360653</phone>
      <email>aghavni_ginosian@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phytomed AB</name>
      <address>
        <city>Vaxtorp</city>
        <state>HL</state>
        <zip>31275</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander G.</last_name>
      <phone>+46733306226</phone>
      <email>ap@phytomed.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016 Mar;109:274-82. doi: 10.1016/j.fitote.2016.02.001. Epub 2016 Feb 2. Review.</citation>
    <PMID>26851175</PMID>
  </reference>
  <reference>
    <citation>Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, Du H, Xu T, Jiang G, Fan G. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother. 2021 Jan;133:110984. doi: 10.1016/j.biopha.2020.110984. Epub 2020 Nov 10. Review.</citation>
    <PMID>33186794</PMID>
  </reference>
  <reference>
    <citation>Loftsson T, Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A. Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug/cyclodextrin complexes. J Pharm Pharmacol. 2016 May;68(5):544-55. doi: 10.1111/jphp.12427. Epub 2015 Jun 9. Review.</citation>
    <PMID>26059798</PMID>
  </reference>
  <reference>
    <citation>Kamigauchi M, Kawanishi K, Ohishi H, Ishida T. Inclusion effect and structural basis of cyclodextrins for increased extraction of medicinal alkaloids from natural medicines. Chem Pharm Bull (Tokyo). 2007 May;55(5):729-33.</citation>
    <PMID>17473458</PMID>
  </reference>
  <reference>
    <citation>Hopwood VL, Pathak S. Improved quality of Giemsa banding by the use of trypsin concentrate. Am Biotechnol Lab. 1994 Oct;12(11):52.</citation>
    <PMID>7765426</PMID>
  </reference>
  <reference>
    <citation>Tannous M, Caldera F, Hoti G, Dianzani U, Cavalli R, Trotta F. Drug-Encapsulated Cyclodextrin Nanosponges. Methods Mol Biol. 2021;2207:247-283. doi: 10.1007/978-1-0716-0920-0_19. Review.</citation>
    <PMID>33113141</PMID>
  </reference>
  <reference>
    <citation>Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo). 2004 Aug;52(8):900-15. Review.</citation>
    <PMID>15304981</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Berberine</keyword>
  <keyword>gamma-cyclodextrin</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Berberine MetX™ Ultra Absorption</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

